Opinion|Videos|May 21, 2024

CDK4/6 Inhibitor Sequencing and NCCN Guidelines in mBC

5. Frank Scimeca, PharmD, MBA, BCOP, leads a discussion on sequencing CDK4/6 inhibitors, comparing their side effect profiles, toxicity benefits, and progression-free survival (PFS) advantages. He emphasizes the need for additional biomarkers and clearer guidance from the NCCN to aid in selecting the most appropriate drug for each patient.


Related to this article